Reports of SARS-CoV-2 breakthrough infections in COVID-19 vaccinated populations
| Study | Location | Vaccine | Population | Breakthrough percentage (%) | Breakthrough counts |
| Dyer16 | USA | BNT162b2 and mRNA-1273 | Entire population | 0.01 | 5800/77 million |
| Hall3 | England | None (prevaccine) | Public hospital workers | 0.67 | 44/6614 |
| PCR/Antibody+ | |||||
| Keehner5 | California,USA | BNT162b2 and mRNA-1273 | UCSD and UCLA healthcare workers | 0.05 | 7/14,990 |
| Pollett18 | USA | BNT162b2 and mRNA-1273 | Military health system | 1.55 | 24/1547 |
| BNT162b2 | 1.42 | 22/1547 | |||
| mRNA-1273 | 0.13 | 2/1547 | |||
| Ramirez43 | USA | BNT162b2, mRNA-1273 and Ad26.COV2.S | University students and employees | 0.55 | 14/2551 |
| BNT162b2 | 0.24 | 6/2551 | |||
| mRNA-1273 | 0.20 | 5/2551 | |||
| Ad26.COV2.S | 0.12 | 3/2551 | |||
| Hacisuleyman44 | USA | BNT162b2 and mRNA-1273 | University students | 4.79 | 2/417 |
| Teran45 | Chicago, USA | Unspecified | Skilled nursing facility staff and residents | 0.15 | 22/14,765 |
| Tenforde29 | US hospitals | BNT162b2 and mRNA-1273 | Hospital patients | 43.9 | 1983/4513 |
| Tenforde42 | US hospitals | BNT162b2 and mRNA-1273×2 doses | Hospital patients | 31 | 212/679 |
| BNT162b2 and mRNA-1273×3 doses | 8 | 10/131 |
UCLA, University of California Los Angeles; UCSD, University of California San Diego.